2 Beaten-Down Stocks to Avoid Right Now
There might be plenty more downside for these biotechs.
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Brighthouse Finl ( NASDAQ:BHF ) , Bath & Body Works ( NYSE:BBWI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - SPS Commerce ( NASDAQ:SPSC ) , Intellia Therapeutics ( NASDAQ:NTLA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran ( nex-z ) in Patients with Transthyretin ( ATTR ) Amyloidosis with Cardiomyopathy - Intellia Therapeutics ( NASDAQ:NTLA )
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baseline
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran ( nex-z ) in Patients with Transthyretin ( ATTR ) Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive follow-up data from the ongoing Phase 1 clinical trial of ...
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran ( lonvo-z ) in Patients with Hereditary Angioedema
CAMBRIDGE, Mass., Nov. 08, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ: NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical data from a pooled analysis of all patients who ...
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
Wall Street may be overestimating these companies' potential.
Block Posts Downbeat Q3 Results, Joins Archer Aviation, DraftKings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Archer Aviation ( NYSE:ACHR ) , AirSculpt Technologies ( NASDAQ:AIRS )
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Friday. Shares of Block, Inc. ( NYSE:XYZ ) fell sharply in pre-market trading after the company reported worse-than-expected third-quarter financial results.
Intellia Therapeutics, Inc. ( NTLA ) Reports Q3 Loss, Misses Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +9.80% and -12.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Maybe Cathie Wood and Wall Street are being too optimistic.
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
ANI Pharmaceuticals ( ANIP ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals ( ANIP ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cathie Wood Just Dumped $7.4 Million Worth Of Palantir And AMD Shares - Here's What Ark Is Buying Instead - Advanced Micro Devices ( NASDAQ:AMD ) , ARK Innovation ETF ( BATS:ARKK )
On Thursday, Cathie Wood-led Ark Invest made significant trades involving Palantir Technologies Inc. ( NASDAQ:PLTR ) , Advanced Micro Devices Inc. ( NASDAQ:AMD ) , Pacific Biosciences of California Inc. ( NASDAQ:PACB ) , and DoorDash Inc. ( NASDAQ:DASH ) .
Meta, eBay, Microsoft And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Cava Group ( NYSE:CAVA ) , Cleveland-Cliffs ( NYSE:CLF )
U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Thursday. Shares of Meta Platforms, Inc. ( NASDAQ:META ) fell sharply in pre-market trading following third-quarter results. Meta posted upbeat earnings for the third quarter on Wednesday.
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - CERo Therapeutics Hldgs ( NASDAQ:CERO ) , Aditxt ( NASDAQ:ADTX )
Shares of Alphabet Inc. ( NASDAQ:GOOGL ) rose sharply in today's pre-market trading as the company reported better-than-expected financial results for the third quarter after the market closed on Wednesday.
Emergent Biosolutions ( EBS ) Beats Q3 Earnings and Revenue Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of +983.33% and +20.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics Stock Is Diving Again: Here's Why - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia Therapeutics Inc ( NASDAQ:NTLA ) shares are tumbling in after-hours trading on Wednesday after the company announced the U.S. Food and Drug Administration ( FDA ) placed a clinical hold on some of its Investigational New Drug ( IND ) applications.
Cathie Wood Just Dumped More Palantir Shares Despite 'Holy Grail' AI Deal - Here's What Ark Bought Instead - Palantir Technologies ( NASDAQ:PLTR )
Cathie Wood-led Ark Invest made significant trades on Tuesday, focusing on companies like DraftKings Inc. ( NASDAQ:DKNG ) , Palantir Technologies Inc. ( NASDAQ:PLTR ) , and Shopify Inc. ( NASDAQ:SHOP ) .
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday - Cadence Bank ( NYSE:CADE ) , Cadence Design Systems ( NASDAQ:CDNS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Jefferies cut Ramaco Resources Inc ( NASDAQ:METC ) price target from $45 to $33.
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cadence Bank ( NYSE:CADE ) , Boot Barn Holdings ( NYSE:BOOT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst Mitch Kummetz downgraded the rating for Boot Barn Holdings Inc ( ...
Cathie Wood Bets Big On Jack Dorsey's Bitcoin-Heavy Block, Adds Amazon And Alibaba - Sells Shopify, Surging Palantir - Amazon.com ( NASDAQ:AMZN )
On Monday, Cathie Wood-led Ark Invest executed significant trades, including a notable purchase of shares in Amazon.com Inc. ( NASDAQ:AMZN ) , Block Inc. ( NYSE:XYZ ) , and Alibaba Group Holding Ltd. ( NYSE:BABA ) . Ark sold shares of Shopify Inc. ( NASDAQ:SHOP ) and Palantir Inc. ( NASDAQ:PLTR ) ...
Gold Falls 3%; Carter's Shares Gain After Q3 Earnings - BIO-key International ( NASDAQ:BKYI ) , Co-Diagnostics ( NASDAQ:CODX )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.51% to 47,449.22 while the NASDAQ rose 1.68% to 23,593.80. The S&P 500 also rose, gaining, 1.01% to 6,860.11. Communication services shares jumped by 1.5% on ...
Why Is Intellia Therapeutics Stock Sinking Monday? - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia Therapeutics Inc. ( NASDAQ:NTLA ) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of its experimental CRISPR therapy, nexiguran ziclumeran ( nex-z ) , following a serious liver-related adverse ...
Nasdaq Surges 300 Points; Keurig Dr Pepper Shares Jump After Q3 Results - BIO-key International ( NASDAQ:BKYI ) , Co-Diagnostics ( NASDAQ:CODX )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 300 points on Monday. Following the market opening Monday, the Dow traded up 0.41% to 47,398.49 while the NASDAQ rose 1.37% to 23,521.66. The S&P 500 also rose, gaining, 0.82% to 6,847.22.
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran ( nex-z )
Conference call today at 8:30 a.m. ET Conference call today at 8:30 a.m. ET ...
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus
Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
Intellia Therapeutics ( NTLA ) Soars 19.7%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Intellia Therapeutics ( NTLA ) Upgraded to Buy: Here's What You Should Know
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday - Century Aluminum ( NASDAQ:CENX ) , Absci ( NASDAQ:ABSI )
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Wednesday. Shares of Dell Technologies Inc. ( NYSE:DELL ) shares rose sharply during Wednesday's session.
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics ( NTLA ) : Here's What You Should Know
The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Intellia Therapeutics ( NTLA ) Outperforming Other Medical Stocks This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
1 Stock Up by 63% This Year That Could Double, According to Wall Street
Some math suggests that even Wall Street is lowballing the stock's potential.
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new ...
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought
The growth investor kicked off this week buying up some high-flying stocks.
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday - Acuity ( NYSE:AYI ) , AES ( NYSE:AES )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday. Shares of Acuity Inc. ( NYSE:AYI ) rose sharply during Wednesday's session following better-than-expected fourth-quarter earnings. It clocked an adjusted EPS of $5.20, beating the analyst consensus ...
Cathie Wood's China Bet: Ark Buys Alibaba's AI Surge And Baidu's Autonomous Future, Dump's Stock Of Crypto-Pivot Brera - ARK Innovation ETF ( BATS:ARKK )
On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Baidu Inc. ( NASDAQ:BIDU ) , Alibaba Group Holding Ltd. ( NYSE:BABA ) , and Brera Holdings PLC ( NASDAQ:BREA ) . ARK Innovation ETF ( BATS:ARKK ) purchased 52,388 shares of Baidu.
What's Going On With Intellia Therapeutics Stock Thursday - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia Therapeutics Inc. ( NASDAQ: NTLA ) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran ( nex-z ) for the treatment of hereditary ATTR amyloidosis with polyneuropathy ( ATTRv-PN ) .
